Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: a study of the ALWP of the EBMT.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8702459 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5365 (Electronic) Linking ISSN: 02683369 NLM ISO Abbreviation: Bone Marrow Transplant Subsets: MEDLINE
    • Publication Information:
      Publication: <2003->: London : Nature Publishing Group
      Original Publication: Basingstoke, Hampshire : Scientific & Medical Division, Macmillan Press, c1986-
    • Subject Terms:
      Isocitrate Dehydrogenase*/genetics ; Leukemia, Myeloid, Acute*/therapy ; Leukemia, Myeloid, Acute*/genetics ; Leukemia, Myeloid, Acute*/mortality ; Hematopoietic Stem Cell Transplantation*/methods ; Nucleophosmin* ; Mutation*; Humans ; Middle Aged ; Male ; Female ; Adult ; Aged ; Adolescent ; Young Adult ; Transplantation, Homologous/methods
    • Abstract:
      Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations have uncertain prognostic implications in AML. We investigate the impact IDH1 and IDH2 mutations in AML patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) in first complete remission (CR1). In total, 1515 adult patients were included, 15.91% (n = 241) carried IDH1 mutation (mIDH1), and 26.27% (n = 398) IDH2 mutation (mIDH2) and 57.82% (n = 876) had no-IDH mutation. NPM1 was frequently encountered with IDH1 mutation (no-IDH group, n = 217, 24.8%, mIDH1, n = 103, 42.7%, mIDH2, n = 111, 27.9%, p < 0.0001). At day 180, the cumulative incidence (CI) of grade II-IV acute graft-versus-host disease (GVHD) was significantly lower in mIDH1 and mIDH2 compared to no-IDH groups (Hazard ratio [HR] = 0.66 (95% CI 0.47-0.91), p = 0.011; HR = 0.73 (95% CI 0.56-0.96), p = 0.025, respectively). In the mIDH1 group, overall survival (OS) was improved compared to no-IDH (HR = 0.68 (95% CI 0.48-0.94), p = 0.021), whereas mIDH2 was associated with lower incidence of relapse (HR = 0.49 (95% CI 0.34-0.7), p < 0.001), improved leukemia free survival (LFS) (HR = 0.7 (95% CI 0.55-0.9), p = 0.004) and OS (HR = 0.74 (95% CI 0.56-0.97), p = 0.027). In the subgroup of NPM1 wild type, only IDH2 was associated with improved outcomes. In conclusion, our data suggest that IDH1 and IDH2 mutations are associated with improved outcomes in patients with AML undergoing allo-HCT in CR1.
      (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
    • References:
      Bolon YTAR, Allbee-Johnson M, Estrada-Merly N, Lee SJ. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, 2022. Accessed from: https://cibmtr.org/CIBMTR/Resources/Summary-Slides-Reports . Accessed on July 30, 2024.
      Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, et al. De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021;127:2049–61. (PMID: 10.1002/cncr.3345833818756)
      El-Cheikh J, Bidaoui G, Saleh M, Moukalled N, Abou Dalle I, Bazarbachi A. Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clin Hematol Int. 2023;5:143–54. (PMID: 10.1007/s44228-023-00041-x3707132810241752)
      Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–1228. (PMID: 10.1182/blood.2022015850357678979479031)
      Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. (PMID: 10.1182/blood.202201686735797463)
      Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–1719. (PMID: 10.1038/s41375-022-01613-1357328319252913)
      Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361:1058–1066. (PMID: 10.1056/NEJMoa0903840196571103201812)
      Asmar F, Søgaard A, Grønbæk K. Chapter 2 - DNA Methylation and Hydroxymethylation in Cancer. In: Gray SG, editor. Epigenetic Cancer Therapy. Boston: Academic Press; 2015. pp. 9–30.
      Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483:474–78. (PMID: 10.1038/nature10860223439013478770)
      Montalban-Bravo G, DiNardo CD. The role of IDH mutations in acute myeloid leukemia. Future Oncol. 2018;14:979–93. (PMID: 10.2217/fon-2017-052329543066)
      Issa GC, DiNardo CD. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm. Blood Cancer J. 2021;11:107. (PMID: 10.1038/s41408-021-00497-1340835088175383)
      TIBSOVO® (ivosidenib) [Package Insert]. 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf .
      IDHIFA® (enasidenib) [Package Insert]. 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf .
      DiNardo CD, Propert KJ, Loren AW, Paietta E, Sun Z, Levine RL, et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood. 2013;121:4917–24. (PMID: 10.1182/blood-2013-03-493197236410163682342)
      Xu Q, Li Y, Lv N, Jing Y, Xu Y, Li Y, et al. Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Clin Cancer Res. 2017;23:4511–22. (PMID: 10.1158/1078-0432.CCR-16-262828246275)
      Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374:2209–2221. (PMID: 10.1056/NEJMoa1516192272765614979995)
      Boddu P, Takahashi K, Pemmaraju N, Daver N, Benton CB, Pierce S, et al. Influence of IDH on FLT3-ITD status in newly diagnosed AML. Leukemia. 2017;31:2526–29. (PMID: 10.1038/leu.2017.24428751773)
      Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079–1089. (PMID: 10.1056/NEJMoa1112304224172033545649)
      Salhotra A, Afkhami M, Yang D, Mokhtari S, Telatar M, Gu D, et al. Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations. Clin Lymphoma Myeloma Leuk. 2019;19:e400–e405. (PMID: 10.1016/j.clml.2019.04.007311554099129101)
      Kunadt D, Stasik S, Metzeler KH, Rollig C, Schliemann C, Greif PA, et al. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation. J Hematol Oncol. 2022;15:126. (PMID: 10.1186/s13045-022-01339-8360645779442956)
      Chen EC, Li S, Eisfeld AK, Luskin MR, Mims A, Jones D, et al. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2021;27:479.e1–e7. (PMID: 10.1016/j.jtct.2021.02.02833840625)
      Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706. (PMID: 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O10204198)
      Andersen PK, Klein JP, Zhang MJ. Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18:1489–500. (PMID: 10.1002/(SICI)1097-0258(19990630)18:12<1489::AID-SIM140>3.0.CO;2-#10398287)
      Hougaard P. Frailty models for survival data. Lifetime Data Anal. 1995;1:255–73. (PMID: 10.1007/BF009857609385105)
      Meggendorfer M, Cappelli LV, Walter W, Haferlach C, Kern W, Falini B, et al. IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies. Leukemia. 2018;32:1249–53. (PMID: 10.1038/s41375-018-0026-z29568090)
      Middeke JM, Metzeler KH, Rollig C, Kramer M, Eckardt JN, Stasik S, et al. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study. Blood Adv. 2022;6:1394–405. (PMID: 10.1182/bloodadvances.2021004934347941768905706)
      Duchmann M, Micol JB, Duployez N, Raffoux E, Thomas X, Marolleau JP, et al. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. Blood. 2021;137:2827–37. (PMID: 10.1182/blood.202001016533881523)
      Parker SJ, Metallo CM. Metabolic consequences of oncogenic IDH mutations. Pharmacol Ther. 2015;152:54–62. (PMID: 10.1016/j.pharmthera.2015.05.003259564654489982)
      Zarnegar-Lumley S, Alonzo TA, Gerbing RB, Othus M, Sun Z, Ries RE, et al. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. Blood Adv. 2023;7:5941–53. (PMID: 10.1182/bloodadvances.20220082823726743910562769)
      Ravindra N, Dillon LW, Gui G, Hourigan CS, Ambinder AJ. Pre- and Post-Transplant Measurable Residual IDH Mutations Are Not Associated with Relapse in Patients with IDH-Mutated AML. Blood. 2022;140:3391–92. (PMID: 10.1182/blood-2022-167374)
      Fathi AT, Kim HT, Soiffer RJ, Levis MJ, Li S, Kim AS, et al. Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies. Blood Adv. 2022;6:5857–65. (PMID: 10.1182/bloodadvances.2022008632361500509649991)
      Muhsen IN, Shyr D, Sung AD, Hashmi SK. Machine Learning Applications in the Diagnosis of Benign and Malignant Hematological Diseases. Clin Hematol Int. 2021;3:13–20. (PMID: 10.2991/chi.k.201130.00134595462)
    • Accession Number:
      EC 1.1.1.41 (Isocitrate Dehydrogenase)
      117896-08-9 (Nucleophosmin)
      0 (NPM1 protein, human)
      EC 1.1.1.41 (IDH2 protein, human)
      EC 1.1.1.42. (IDH1 protein, human)
    • Publication Date:
      Date Created: 20240814 Date Completed: 20241102 Latest Revision: 20241102
    • Publication Date:
      20241103
    • Accession Number:
      10.1038/s41409-024-02384-2
    • Accession Number:
      39143183